Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Psychiatry Res ; 272: 86-92, 2019 02.
Article in English | MEDLINE | ID: mdl-30579187

ABSTRACT

Research into hallucinations typically regards them as single sensory or unimodal experiences leading to a comparative neglect of co-occurring multi-sensory hallucinations (MSH). People with psychosis who have visual hallucinations (VH) report high rates of hallucinations in other senses (auditory, olfactory, tactile). However, it is not known if this is similar to other groups who report VH. Consequently, this study explored MSH in four different patient groups who all had current VH. Archival data from standardised assessments of visual hallucinations in people with psychosis (n = 22), eye disease (ED) (n = 82), Lewy body Dementia (LBD) (n = 41), and Parkinson's disease (PD) (n = 41) determined the presence of MSH. People with psychosis and visual hallucinations reported significantly higher rates of MSH (auditory, 73%; tactile, 82%; olfactory/gustatory hallucinations, 27%) than the LBD group (auditory, 21%; tactile, 28%; olfactory/gustatory, 6%), ED (auditory, 1%; tactile, 11%; olfactory/gustatory, 0%) and PD patients (auditory, 3%; tactile, 8%; olfactory/gustatory, 3%). Regardless of diagnostic grouping, participants with MSH reported greater conviction that the VH were real, and reported greater distress. People with psychosis with VH report high rates of MSH unlike groups of older adults with VH. These between group differences in MSH prevalence have implications for clinical practice and theory.


Subject(s)
Eye Diseases/physiopathology , Hallucinations/physiopathology , Lewy Body Disease/physiopathology , Parkinson Disease/physiopathology , Psychotic Disorders/physiopathology , Visual Perception/physiology , Aged , Eye Diseases/complications , Female , Hallucinations/etiology , Humans , Lewy Body Disease/complications , Male , Middle Aged , Parkinson Disease/complications , Psychotic Disorders/complications
2.
Psychol Med ; 48(10): 1608-1615, 2018 07.
Article in English | MEDLINE | ID: mdl-29310738

ABSTRACT

BACKGROUND: The longstanding association between the major histocompatibility complex (MHC) locus and schizophrenia (SZ) risk has recently been accounted for, partially, by structural variation at the complement component 4 (C4) gene. This structural variation generates varying levels of C4 RNA expression, and genetic information from the MHC region can now be used to predict C4 RNA expression in the brain. Increased predicted C4A RNA expression is associated with the risk of SZ, and C4 is reported to influence synaptic pruning in animal models. METHODS: Based on our previous studies associating MHC SZ risk variants with poorer memory performance, we tested whether increased predicted C4A RNA expression was associated with reduced memory function in a large (n = 1238) dataset of psychosis cases and healthy participants, and with altered task-dependent cortical activation in a subset of these samples. RESULTS: We observed that increased predicted C4A RNA expression predicted poorer performance on measures of memory recall (p = 0.016, corrected). Furthermore, in healthy participants, we found that increased predicted C4A RNA expression was associated with a pattern of reduced cortical activity in middle temporal cortex during a measure of visual processing (p < 0.05, corrected). CONCLUSIONS: These data suggest that the effects of C4 on cognition were observable at both a cortical and behavioural level, and may represent one mechanism by which illness risk is mediated. As such, deficits in learning and memory may represent a therapeutic target for new molecular developments aimed at altering C4's developmental role.


Subject(s)
Cognitive Dysfunction/physiopathology , Complement C4a/metabolism , Major Histocompatibility Complex/genetics , Memory Disorders/physiopathology , Psychotic Disorders/genetics , Psychotic Disorders/physiopathology , Temporal Lobe/physiopathology , Adult , Cognitive Dysfunction/diagnostic imaging , Female , Functional Neuroimaging , Gene Expression/genetics , Humans , Ireland , Magnetic Resonance Imaging , Male , Memory Disorders/diagnostic imaging , Memory, Short-Term/physiology , Mental Recall/physiology , Middle Aged , Psychotic Disorders/diagnostic imaging , Temporal Lobe/diagnostic imaging
3.
Psychol Med ; 42(6): 1119-29, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22008511

ABSTRACT

BACKGROUND: Experience Sampling Methodology (ESM) is ideally suited to test the predictions, and inform the development of contemporary cognitive models of depression. Yet there has been no systematic examination of ESM in depression research. METHOD: A search of databases (PsychARTICLES, PsycINFO, AMED, Ovid Medline and CINAHL) was conducted to identify studies published within the last 25 years investigating major depressive disorder (MDD) using ESM. RESULTS: Altogether, 19 studies using ESM, or comparable methodologies, with clinically depressed individuals were identified and critically reviewed. The identified studies examined six aspects of MDD: methodological issues; positive and negative affect; cortisol secretion; antidepressant treatment; work performance; genetic risk factors. CONCLUSIONS: Despite some methodological limitations of existing studies, ESM has made a significant contribution to our current understanding of depression by consolidating existing theories, uncovering new and clinically relevant findings and identifying questions for future research. This review concludes by introducing the possibility of using ESM as an intervention tool in clinical practice and proposing that ESM could be useful for furthering knowledge of the causes of MDD.


Subject(s)
Affect , Depressive Disorder, Major/psychology , Models, Psychological , Research Design , Antidepressive Agents/therapeutic use , Circadian Rhythm , Databases, Bibliographic , Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/genetics , Employment , Genetic Predisposition to Disease , Humans , Hydrocortisone/metabolism , Quality of Life , Stress, Psychological/psychology
SELECTION OF CITATIONS
SEARCH DETAIL
...